Cayston is an inhalable formulation of the monobactam antibacterial aztreonam and was developed by Gilead. It inhibits cell wall synthesis in aerobic Gram-negative bacteria, including Pseudomonas aeruginosa, one of the most common pathogens found in patients with cystic fibrosis. Treatment with Cayston requires nebulization of the aztreonam solution, and the recommended dosing is three times daily.
LIST OF FIGURES
12 Figure 1: Cayston for cystic fibrosis – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Cayston for cystic fibrosis
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Cayston for cystic fibrosis
16 Figure 4: Cayston sales for cystic fibrosis across the US and five major EU markets, by country, 2016–25
LIST OF TABLES
6 Table 1: Cayston drug profile
8 Table 2: Cayston Phase III data in cystic fibrosis
17 Table 3: Cayston sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016–25
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726